Professor Mark Blaskovich is an antibiotic hunter and Director of Translation at the Institute for Molecular Bioscience at The University of Queensland. He is co-founder and former Director of the Centre for Superbug Solutions at IMB.

A medicinal chemist with 15 years of industrial drug development experience prior to his academic career, Mark has been developing new antibiotics to treat drug resistant pathogens and using modified antibiotics to detect bacterial infections. He is a co-founder of the Community for Open Antimicrobial Drug Discovery, a global antibiotic discovery initiative, and has led a number of UQ-industry collaborations focused on antibiotic development. An inventor on eleven patent families, Mark has developed drugs in clinical trials, published more than eighty research articles, and received over $10m in grant funding.

My research group specializes in the detection, isolation, identification and evaluation of biologically active small molecules from Nature (natural products). We acquire valuable knowledge on how and why natural products are made, and apply this knowledge to better understand living systems, and solve important scientific and societal challenges.

To achieve these goals we have established specialist capabilities that extend across;

Microbiology – the isolation, characterization and cultivation of bacterial and fungal strains.

Chemistry – the extraction and fractionation of natural extracts, the purification, chemical and spectroscopic characterization, and structure elucidation of natural products, and the use of synthetic and medicinal chemistry to explore bioactive scaffolds.

Biology – to evaluate extracts and natural products against an array of bioassays, leading to new human pharmaceuticals that target such indications as infectious and neurodegenerative diseases, cancer, pain and epilepsy, as well as new animal health products and new crop protection agents.

Brett Collins is an NHMRC Career Development Fellow and head of the Molecular Trafficking Lab at UQ's Institute for Molecular Bioscience. He was a lead investigator in the seminal structural studies of AP2, the protein adaptor molecule central to clathrin-mediated endocytosis, and has since defined the molecular basis for the function of critical proteins regulating membrane trafficking and signalling at the endosome organelle. His team is now focused on understanding how discrete molecular interactions between proteins and lipids control these processes in human cells.

Associate Professor Collins was awarded his PhD in 2001 and has published over 75 papers including in Cell, Nature, Nature Structural and Molecular Biology, Developmental Cell, and The Proceedings of the National Academy of Sciences USA, altogether cited more than 3100 times. He is the recipient of 3 prestigious fellowships, including a previous Career Development Award from the National Health and Medical Research Council and a Future Fellowship from the Australian Research Council, and was awarded the University of Queensland Research Excellence Award in 2008. In 2015 he was awarded the Emerging Leader Award of the ANZSCDB and in 2016 the Merck Research Medal from the ASBMB. He is currently the President of the Queensland Protein Group.

David Craik (AO, FRS, FAA) is in the Centre for Chemistry and Drug Discovery at the Institute for Molecular Bioscience, The University of Queensland, Australia. He discovered the cyclotide family of circular proteins and has characterized the structures of many animal toxins including conotoxins from cone snail venoms. He heads a research team of 35 researchers whose current work focuses on applications of circular proteins, drugs in plants, toxins and NMR in drug design.

He is author of over 810 scientific papers, including 14 in Nature publications (Nature/Nature Communications/Nature Neuoroscience/Nature Structural Biology/Nature Chemical Biology/Nature Chemistry/Scientific Reports/Nature Protocols, 1 in Science, 12 in PNAS, 9 in JACS, 3 in Chemical Reviews, and 16 in Angewandte Chemie. He has been elected as a Fellow of the Royal Society and a Fellow of the Australian Academy of Science, appointed as an Officer (AO) of the Order of Australia and has received numerous awards for his research, including the Ralph F. Hirschmann Award from the American Chemical Society (2011), Ramaciotti Medal for Excellence in Biomedical Research (2014), GlaxoSmithKline Award for Research Excellence (2014), the Vincent du Vigneaud Award from the American Peptide Society (2015),the FAOBMB Award for Research Excellence (2015) and the Cathay Award from the Chinese Peptide Society (2018). He received the Australian Academy of Science David Craig Medal in 2023. He is an Honorary Professor of Jinan University, Guangzhou and has an Honorary Doctorate from Kalmar University in Sweden.

Biography

David Craik obtained his PhD in organic chemistry from La Trobe University in Melbourne, Australia and undertook postdoctoral studies at Florida State and Syracuse Universities before taking up a lectureship at the Victorian College of Pharmacy in 1983. He was appointed Professor of Medicinal Chemistry and Head of School in 1988. He moved to University of Queensland in 1995 to set up a new biomolecular NMR, held an Australian Research Council Laureate Fellow (2015-2020) and is currently a NHMRC Fellow, as well as Director of the Australian Research Council Centre of Excellence in Peptide and Protein Science.

Key Discoveries

David Craik has made discoveries of new classes of proteins, generated new knowledge on their structure and function, and used this information to design and chemically re-engineer new classes of protein-based drug leads and agricultural pest control agents. In particular, his major achievements are:

• the discovery of cyclotides, the largest known family of circular proteins. As well as a circular backbone, cyclotides contain a knotted arrangement of cross-linking disulfide bonds, making them remarkably stable. His discovery of these proteins was sparked in part from anecdotal reports of medicinal practices in Africa where women make a tea from the plant Oldenlandia affinis by boiling it in water and sipping it during labour to accelerate child birth. He determined the structure of the bioactive component of this medicinal tea and found that it had an unprecedented head-to-tail cyclic peptide backbone combined with a cystine knot.
• the first structural and functional characterizations of prototypic circular proteins in higher organisms - Professor Craik was one of the first to recognize that other families of ribosomally synthesized cyclic peptides exist. As examples from bacteria and animals emerged, Professor Craik was at the forefront of their structural characterization, reporting the first structures of theta-defensins from animals and the threaded lasso peptide microcin J25 from bacteria, as well as new examples of cyclic peptides from plants.
• the development of artificially cyclized peptide toxins as drug leads – he developed an orally active peptide that is 100 times more potent than the leading clinically used drug for neuropathic pain.

Research Training

Professor Craik has trained more than 70 PhD students. He was awarded UQ's Research Supervision Excellence Award in 2007 on the basis of his mentoring and innovations in postgraduate training, including his "writing retreats" to mentor students and postdocs on science writing skills. He received the Institute for Molecular Bioscience Individual Leadership Award in 2019. He was awarded an honorary doctorate from Kalmar University, Sweden for his contributions to international student exchange programs, and is an Honorary Professor of Jinan University, Guangzhou.

Professional Activities

Professor Craik founded and chaired the 1st, 2nd and 3rd International Conferences on Circular Proteins (2009, 2012 and 2015) and was on the Scientific Program Committee for ISMAR 2021. He is on the Boards of six international journals, including Angewandte Chemie, ACS Chemical Biology, Chemical Biology and Drug Design, and ChemBioChem. He was on the Council of the American Peptide Society (2015-2021). He was the director two Brisbane-based biotech companies. He is on the Scientific Advisory Boards of James Cook University's Centre for Biodiscovery and Molecular Development of Therapeutics (BMDT), the University of Wollongong's Illawara Health and Medical Research Institute (IHMRI) and Enzytag. He conceived and supports two publicly accessible databases - Cybase on circular proteins (www.cybase.org.au), and conotoxins (www.conoserver.org).

David Evans is an NHMRC Leadership Fellow and Professor of Statistical Genetics at the University of Queensland Institute for Molecular Bioscience. He is a winner of the NHMRC Marshall and Warren Award.

He completed his PhD in Statistical Genetics at the University of Queensland in 2003, before undertaking a four-year post-doctoral fellowship at the Wellcome Trust Centre for Human Genetics, University of Oxford where he worked as part of the The International HapMap Consortium and co-led the analysis of four diseases within the first Wellcome Trust Case Control Consortium. In 2007 he moved to take up a Senior Lecturer position at the University of Bristol where he led much of the genome-wide association studies work in the Avon Longitudinal Study of Parents and Children (ALSPAC). In 2013 he returned to take up a chair at the University of Queensland whilst continuing to lead an MRC Programme in statistical genetics at the University of Bristol.

His research interests include the genetic mapping of complex traits and diseases (including birthweight and other perinatal traits, osteoporosis, ankylosing spondylitis, sepsis, laterality) and the development of statistical methodologies in genetic epidemiology including approaches for gene mapping, individual risk prediction, causal modelling and dissecting the genetic architecture of complex traits. He has a particular interest in Mendelian randomization and has used it and other causal methods to investigate the Developmental Origins of Health and Disease (DOHaD)- the idea that adverse intrauterine exposures lead to increased risk of disease in later life.

He is Academic Codirector at the NIH funded International Workshop on Statistical Genetics Methods and is faculty on the European Programme in Educational Epidemiology.

He is Associate Editor at the International Journal of Epidemiology and Behavior Genetics journals.

Professor Fairlie is an NHMRC Research Investigator Fellow (Level 3) (2022-present), a Node Leader of the ARC Centre of Excellence for Innovations in Peptide Protein Science, one of four Centre Directors and former Head of the Division of Chemistry of Structural Biology at the Institute for Molecular Bioscience (since 2009), and an Affiliate Professor of the School of Chemistry and Molecular Biosciences. He was previously an NHMRC Senior Principal Research Fellow (2012-2021), a Node Leader at the ARC Centre of Excellence in Advanced Molecular Imaging (2014-2021), an ARC Federation Fellow (2006-2011), an ARC Professorial Fellow (2002-2006), and Scientific Director and Chief Scientific Officer of a startup company. He undertook postdoctoral studies at Stanford University and University of Toronto, postgraduate studies at Australian National University and University of New South Wales, and undergraduate studies at University of Adelaide.

His research group works across the disciplines of chemistry (synthesis, structure, reaction mechanisms), biochemistry (enzyme inhibitors, protein-protein interactions, GPCRs, transcription factors), immunology (innate immune cells in health and disease, mucosal T cells), and pharmacology (molecular pharmacology and human cell signalling, experimental pharmacology in rodent models of human diseases). He has published over 480 scientific journal articles in high impact chemistry journals (e.g. Chem Rev, Acc Chem Res, J Am Chem Soc, Angew Chem Int Edit, Chem Sci, J Med Chem, Org Lett, J Org Chem) and biology journals (e.g. Nature, Science, Nat Rev Endocrinol, Mol Cancer, Immunity, Nature Immunology, Science Immunology, Am J Resp Crit Care Med, J Hepatol, Trends Immunol, Mol Neurodegen, Adv Drug Deliv Rev, Nature Communications, Trends Pharmacol Sci, J Exp Med, J Clin Invest, Kidney Int, Arthritis & Rheum, Science Advances, Pharmacol Ther, Cancer Res, Proc Natl Acad Sci USA, Dev Cell, Curr Biol, J Cell Biol, Cell Reports, PloS Biol, Br J Pharmacol, JCI Insight, Diabetes, Mucosal Immunol, etc). He has been a Highly Cited Researcher (Clarivate Analytics), with over 37,000 citations and 113 publications with over 100 citations (Google Scholar), and has collaborated with many of the world's largest pharmaceutical and biotechnology companies.

Dr Gordon’s research is focused on the formation and maintenance of the blood and lymphatic vascular systems. Vessels form complex branched networks that supply oxygen and nutrients to all body tissues. The signals controlling blood vessel expansion, identity and migration are all downstream of a single, common complex at the cell surface, yet exactly how this diverse range of functions is differentially regulated, depending on the physiological need, remains unknown.

The specific focus of Dr Gordon’s research is to determine the precise molecular signals that control cell adhesion within the vessel wall the surrounding environment. If the signals controlling cell adhesion become deregulated, normal vessel growth and function is lost. This contributes to the progression of a wide range of human diseases, including cancer growth and metastasis, diabetic eye disease and stroke. Dr Gordon aims to use novel biological models, biochemical assays and imaging techniques to better understand vessel biology, which will enable improved treatment of disease and aid in the development of vascularised, bioengineered organs.

Dr Gordon received her Bachelor of Science (2005) and PhD (2011) from The University of Adelaide, after which she undertook six years of postdoctoral studies at Yale University in the USA and Uppsala University in Sweden. With the support of an ARC DECRA Fellowship, Dr Gordon relocated to IMB in 2017 to establish her independent research career as an IMB Fellow. In 2019, she was appointed as Group Leader of the Vessel Dynamics Laboratory.

Centre for Solar Biotechnology: Prof Ben Hankamer is the founding director of the Solar Biofuels Consortium (2007) and Centre for Solar Biotechnology (2016) which is focused on developing next generation microalgae systems. These systems are designed to tap into the huge energy resource of the sun (>2300x global energy demand) and capture CO2 to produce a wide-range of products. These include solar fuels (e.g. H2 from water, oil, methane and ethanol), foods (e.g. health foods) and high value products (e.g. vaccines produced in algae). Microalgae systems also support important eco-services such as water purification and CO2 sequestration. The Centre is being launched in 2016/2017 and includes approximately 30 teams with skills ranging from genome sequencing through to demonstration systems optimsation and accompanying techno-economis and life cycle analysis. The Centre teams have worked extensively with industry.

Structural Biology: The photosynthetic machinery is the biological interface of microalgae that taps into the huge energy resource of the sun, powers the biosphere and produces the atmospheric oxygen that supports life on Earth. My team uses high resolution single particle analysis and electron tomography to solve the intricate 3D architecture of the photosynthetic machinery to enable structure guided design of high efficiency microalgae cell lines and advanced artificial solar fuel systems.

Kindly visit my laboratory's webpage for more information

Dr Quan Nguyen is a Group Leader at the Institute for Molecular Bioscience (IMB), The University of Queensland. He is leading the Genomics and Machine Learning (GML) lab to study neuroinflammation and cancer-immune cells at single-cell resolution and within spatial morphological tissue context. His research interest is about revealing gene and cell regulators that determine the states of the complex cancer and neuronal ecosystems. Particularly, he is interested in quantifying cellular diversity and the dynamics of cell-cell interactions within the tissues to find ways to improve cancer diagnosis or cell-type specific treatments or the immunoinflammation responses that cause neuronal disease.

Using machine learning and genomic approaches, his group are integrating single-cell spatiotemporal sequencing data with tissue imaging data to find causal links between cellular genotypes, tissue microenvironment, and disease phenotypes. GML lab is also developing experimental technologies that enable large-scale profiling of spatial gene and protein expression (spatial omics) in a range of cancer tissues (focusing on brain and skin cancer) and in mouse brain and spinal cord.

Dr Quan Nguyen completed a PhD in Bioengineering at the University of Queensland in 2013, postdoctoral training in Bioinformatics at RIKEN institute in Japan in 2015, a CSIRO Office of Chief Executive (OCE) Research Fellowship in 2016, an IMB Fellow in 2018, an Australian Research Council DECRA fellowship (2019-2021), and is currently a National Health and Medical Research Council leadership fellow (EL2). He has published in top-tier journals, including Cell, Cell Stem Cell, Nature Methods, Nature Protocols, Nature Communications, Genome Research, Genome Biology and a prize-winning paper in GigaScience. In the past three years, he has contributed to the development of x8 open-source software, x2 web applications, and x4 databases for analysis of single-cell data and spatial transcriptomics. He is looking for enthusiastic research students and research staff to join his group.

Career Summary: 2009: PhD, University of Michigan, USA with training in cardiac physiology, modelling myocardial ischemia in vivo and in vitro, and development of therapeutic approaches for myocardial ischemia; 2009–2015: Postdoctoral Research Fellow, University of Washington, Institute for Stem Cell and Regenerative Medicine, USA with training in stem cell biology, genomics, genome editing, and cell therapeutics for ischemic heart disease; 2015–current: Group Leader, University of Queensland (UQ), Institute for Molecular Bioscience; 2022-current: Associate Professor, UQ; 2018–2021 and 2023-2026: National Heart Foundation Future Leader Fellow. Dr. Palpant's research team has expertise in human stem cell biology, computational genomics, and cardiac physiology, which enables them to translate outcomes from cell biology and genomics to disease modelling, drug discovery, and preclinical modelling.

Our research focuses on understanding how cells work and what goes wrong in disease. We are studying the role of cellular organelles in defence against pathogens, the molecular changes underlying muscle disease, and optimising methods to deliver therapeutics to specific cell types in whole animals.

Professor Robert Parton is an ARC Laureate Fellow, a group leader in the IMB Centre for Cell Biology of Chronic Disease, and Deputy Director of the Centre for Microscopy and Microanalysis. He is a Fellow of the Australian Academy of Science and an Associate Member of EMBO.

Professor Kate Schroder heads the Inflammasome Laboratory and is Director of the Centre for Inflammation and Disease Research at the Institute for Molecular Bioscience (IMB), University of Queensland, as an NHMRC Leadership Fellow. Kate's graduate studies defined novel macrophage activation mechanisms and her subsequent postdoctoral research identified surprising inter-species divergence in the inflammatory programs of human versus mouse macrophages. As an NHMRC CJ Martin Fellow in Switzerland, Kate trained with the pioneer of inflammasome biology, Jürg Tschopp. The IMB Inflammasome Laboratory, which Kate heads, investigates the molecular mechanisms governing inflammasome activity and caspase activation, the cellular mediators of inflammasome-dependent inflammation, and mechanisms of inflammasome inhibition by cellular pathways and small molecule inhibitors.

Kate is a co-inventor on patents for small molecule inhibitors of the NLRP3 inflammasome, currently under commercialisation by Inflazome Ltd. Inflazome Ltd was recently acquired by Roche in a landmark deal – one of the largest in Australian and Irish biotech history. The acquisition gives Roche full rights to Inflazome's portfolio of inflammasome inhibitors. Two of the company's drug candidates are in clinical trials for the treatment of debilitating conditions such as cardiovascular disease, arthritis and neurodegenerative diseases such as Parkinson's, Alzheimer's and motor neuron disease.

Kate has authored more than 140 publications, featuring in journals such as Science, Cell, Nature Genetics, Nature Medicine, Nature Chemical Biology, Journal of Experimental Medicine and PNAS USA, and her work has been cited more than 35,000 times. Kate is an Editorial Board Member for international journals including Science Signaling, Clinical and Translational Immunology and Cell Death Disease. She is the recipient of the 2022 Women in Technology Excellence in Science Award, 2020 Nancy Mills Award for Women in Science, 2019 ANZSCDB Emerging Leader Award, 2019 Merck Research Medal, 2014 Milstein Young Investigator Award, 2013 Tall Poppy Award, 2012 Gordon Ada Career Award, 2010 QLD Premier's Postdoctoral Award, and the 2008 Society for Leukocyte Biology's Dolph Adams Award.

INFLAMMASOME LABORATORY RESEARCH

During injury or infection, our body's immune system protects us by launching inflammation. But uncontrolled inflammation drives diseases such as gout, diabetes, neurodegenerative disease and cancer. The Inflammasome Lab is defining the molecular and cellular processes of inflammation. We seek to unravel the secrets of inflammasomes – protein complexes at the heart of inflammation and disease – to allow for new therapies to fight human diseases.

The Inflammasome Laboratory integrates molecular and cell biology approaches with in vivo studies to gain a holistic understanding of inflammasome function during infection, and inflammasome dysfunction in human inflammatory disease. Current research interests include the molecular mechanisms governing inflammasome activity and caspase activation, the cellular mediators of inflammasome-dependent inflammation, and inflammasome suppression by autophagy and small molecule inhibitors.

Professor Jennifer Stow is a molecular cell biologist, an NHMRC Leadership Fellow and head of the Protein Trafficking and Inflammation research laboratory in The University of Queensland's Institute of Molecular Bioscience (IMB). Her previous leadership appointments include as Division Head and Deputy Director (Research) at IMB (12 years) and she currently serves on national and international advisory boards, editorial boards and steering committees, and as an elected Associate Member of the European Molecular Biology Organisation (EMBO).

Jenny Stow received her undergraduate and PhD qualifications at Melbourne's Monash University before undertaking postdoctoral training in the Department of Cell Biology at Yale University School of Medicine, USA. With training as a microscopist in kidney research, she gained further experience at Yale as a postdoc in the lab of eminent cell biologist and microscopist, Dr Marilyn Farquhar, where protein trafficking was both a theme and a passion. Jenny then took up her first faculty appointment as an Assistant Professor in the Renal Unit at Massachusetts General Hospital (MGH) and Harvard Medical School in Boston USA, where her research uncovered new roles for a class of enzymes, GTPases, in regulating trafficking within cells. At MGH her research also formed part of a highly successful NIH Renal Cell Biology Program. In late 1994, Jenny moved her research lab back to Australia, to The University of Queensland, in late 1994 as a Wellcome Trust International Medical Research Fellow. As part of IMB since, the Stow lab has continued a focus on protein trafficking, including pioneering live-cell imaging, to spearhead their work on trafficking in inflammation, cancer and chronic disease. Major discoveries include identifying new proteins and pathways for recycling adhesion proteins in epithelial cells, inflammatory cytokine secretion in macrophages and immune signalling through Toll-like receptors in inflammation and infection. Small GTPases of the Rab family, signalling adaptors and kinases feature among the molecules studied in the Stow lab for their functional roles and their potential as drug targets in inflammation and cancer. A keen focus is to understand the role of the fluid uptake pathway, macropinocytosis, in controlling inflammation, cancer and mucosal absorption.

Professor Stow has been awarded multiple career fellowships including from American Heart Association, Wellcome Trust and NHMRC. She has published >200 papers, cited over 15,500 times and she is the recipient of awards and honours, most recently including the 2019 President's Medal from the Australia and New Zealand Society for Cell and Developmental Biology. She is also academic head of IMB Microscopy, a world-class fluorescence microscopy and image analysis facility. Her research is funded by a variety of agencies and industry partnerships, in addition to NHMRC and ARC, including through the ARC Centre of Excellence in Quantum Biotechnology, QUBIC. The Stow lab work with national and international collaborators and welcome students and postdoctoral trainees to participate in their research. We value having a diverse, inclusive and supportive culture for research and celebrate the many diverse and wonderful successes of Stow lab alumni.

Matt Sweet is an NHMRC Leadership Fellow, Group Leader, and Director of Higher Degree Research (DHDR) at the Institute for Molecular Bioscience (IMB) at The University of Queensland, Brisbane, Australia. He was the founding Director of the IMB Centre for Inflammation and Disease Research (2014-2018), also serving as Deputy Head of the IMB Division of Cell Biology and Molecular Medicine during this period. Matt studies innate immunity, the body's danger sensing system that responds to infection, injury and dysregulated homeostasis, and the role of this system in health and disease. Matt's research team focuses on manipulating the innate immune system for the development of anti-infective and anti-inflammatory strategies. To do so, his lab characterizes the roles of specific innate immune pattern recognition receptors and their downstream signalling pathways/gene products in inflammatory disease processes, as well as in host responses to bacterial pathogens. He has authored >175 journal articles and book chapters, including in Science (2), Science Translational Medicine, Science Immunology, Nature Immunology, Nature Genetics, Nature Communications (4), PNAS USA (6) and Journal of Experimental Medicine (2), and his career publications have accrued >19,000 citations.

Biography

I was awarded a PhD (The University of Queensland) in 1996 for my research under the supervision of Prof David Hume into gene regulation in macrophages, immune cells with important roles in health and disease. I subsequently undertook a short postdoctoral position in the same laboratory, focusing on the activation of macrophages by pathogen products. I then embarked on a CJ Martin post-doctoral training fellowship with Prof Eddy Liew, FRS at the University of Glasgow in Scotland. Returning to The University of Queensland, I had a prominent role within the Cooperative Research Centre for Chronic Inflammatory Diseases (including as UQ node head from 2007-2008) and was appointed as a Group Leader at the IMB in 2007. I have continued fellowship support since this time, including as an ARC Future Fellow, an NHMRC Senior Research Fellow and an NHMRC Leadership Fellow (current, from 2021).

Key discoveries

CpG-containing DNA as an activator of innate immunity, and characterization of the receptor (TLR9) detecting this microbial component.

The IL-1 receptor family member ST2 as a critical regulator of innate immunity and inflammation.

Inflammatory and antimicrobial functions of histone deacetylase enzymes (HDACs) in macrophages.

Effects of the growth factor CSF-1 on inflammatory responses in macrophages.

Mechanisms responsible for divergence in TLR responses between human and mouse macrophages, as well as the functional consequences of such divergence.

TLR-inducible zinc toxicity as an antimicrobial weapon of macrophages and the identification of defects in this pathway in cystic fibrosis.

Host evasion strategies used by the bacterial pathogens Salmonella enterica serovar Typhimurium and uropathogenic E. coli.

SCIMP as a novel TLR adaptor that mediates TLR tyrosine phosphorylation and selective cytokine outputs.

Genes and pathways associated with the severity of chronic liver disease.

Molecular mechanisms controlling macrophage immunometabolism, as well as associated inflammatory and antimicrobial responses.

Anti-inflammatory and antibacterial activities of the metabolite ribulose-5-phosphate.

Research training

I have supervised or co-supervised 29 completed PhD students and 22 completed honours students, as well as 9 post-doctoral researchers. Many of my former staff and students continue to have active research careers around the world (USA, UK, Europe, Australia), including as independent laboratory heads. I currently supervise 5 PhD students in my laboratory, co-supervise 4 PhD students in other laboratories, and oversee the research activities of 2 post-doctoral researchers in my group. Current and former staff/students have received numerous fellowships and awards during their research careers (e.g. ARC DECRA, NHMRC CJ Martin fellowship, UQ post-doctoral fellowship, Smart State scholarship). I have also examined >25 PhD theses in the fields of innate immunity, inflammation and host defence.

Professional activities

I am an editorial board member of the Journal of Leukocyte Biology and Seminars in Cell & Developmental Biology, and have served as an editorial board member for several other journals in the past e.g. Immunology and Cell Biology. I have served on NHMRC project grant review panels in 2007, 2008, 2009, 2012 (as panel chair) and 2014, NHMRC Ideas panels in 2020 and 2024, NHMRC Investigator panels in 2021 and 2022, as well as a member of the NHMRC RGMS user reference group committee from 2010-2012. I acted as national representative for the Australasian Society of Immunology (ASI) Infection and Immunity special interest group from 2012-2017. At UQ, I served as chair of an animal ethics committee from 2013-2014, and co-organized the UQ Host-Pathogen interaction network from 2007-2010 (prior to the establishment of the Australian Infectious Diseases Research Centre). I am currently Director of Higher Degree by Research at IMB, overseeing HDR student recruitment and training.

I have made extensive contributions to conference organization in my discipline. I co-organized the national TLROZ2009 and TLROZ2012 conferences, I organized the first ever Australasian Society for Immunology (ASI) Infection and Immunity workshop (2009), was chair of the ASI Program Committee and co-organizer of the Infection and Immunity workshop for ASI2017, and I co-organized the annual IMB Inflammation Symposium (2014-2018). I also co-chaired the 2019 World Conference of Inflammation (Sydney, September 2019). In addition, I have been a member of the organizing committee for ASI2009, the 2014 International Cytokine and Interferon Society conference, the Lorne Infection and Immunity conference (2014-2020), and the Brisbane Immunology Group annual meeting (2008 to the present).

I am an NHMRC Leadership Fellow with joint apointments at the Institute for Molecular Bioscience (IMB) and School of Pharmacy, UQ. My research interests lie in the fields of peripheral pain mechanisms, target identification and analgesic drug discovery. I investigate the contribution of ion channels to sensory neuronal physiology using highly subtype-selective toxins isolated from venomous animals with the aim to develop novel analgesics with improved efficacy and tolerability.

Visscher joined the University of Queensland in 2011, where he is Professor of Quantitative Genetics. He is a Laureate Fellow of the Australian Research Council. Visscher was elected a Fellow of the Australian Academy of Science in 2010, a Fellow of the Royal Society (London) in 2018 and a Foreign Member of the Royal Netherlands Academy of Arts and Sciences in 2018.

Visscher's research is about genetic variation for complex traits (including quantitative traits and disease) in populations, with the broad aim to understand and quantify the causes and consequences of human trait variation.

Prof Peter Visscher, Prof Naomi Wray and Prof Jian Yang together comprise the Executive Team of the Program in Complex Trait Genomics (PCTG). PCTG comprises a critical mass of more than 30 post-doctoral researchers plus research assistants and students, all supported by external grant funding. Their skills lie in the ability to develop and apply statistical methods within the framework of quantitative, population and statistical genetics and to use theory to understand and predict results from data analyses. They play leading roles in the international research consortia. The focus of current research activities is in the detection and fine-mapping of loci underlying complex traits (including common disease), based upon theoretical studies and applications of methods to large datasets, in population genetics studies using theoretical approaches and high-density genetic marker data, and in systems genomics studies.

Dr Melanie White heads the Dynamics of Morphogenesis Lab at the Institute for Molecular Bioscience (IMB), University of Queensland and is an ARC Future Fellow. She completed a PhD in Neuroscience at University College London followed by postdoctoral research at The University of Edinburgh. During this time Mel engineered viruses to modulate gene expression in the brain to investigate neuronal function and as a therapeutic approach for neurodegenerative disease. Her work was published in Neuron and PNAS, featured in Nature Reviews Neuroscience and received extensive international media coverage (including the BBC and The Guardian).

In 2012 Mel switched fields to apply quantitative imaging in developmental biology. Her work revealed key mechanisms driving the earliest morphogenetic events in mammalian embryogenesis and was published in Cell, Science, Nature Cell Biology, Developmental Cell and Nature Protocols. Her research was featured on the cover of multiple journals including Cell and she was awarded the inaugural American Society for Cell Biology Porter Prize for Research Excellence (2018).

In 2020, Mel joined the IMB where she will combine her passion for neuroscience and developmental biology to investigate the dynamics of neural tube morphogenesis.

Research overview

The brain and the spinal cord control most of the functions of the body and the mind, yet the dynamics of how they first form is poorly understood. Both structures arise from a common precursor, the neural tube, which forms very early in embryonic development. To generate the forces that sculpt and shape the neural tube, changes in cellular architecture must be tightly coordinated in space and time. These morphological rearrangements occur concurrently with biochemical signalling pathways that specify early neural cell fates.

Our research aims to understand how cellular properties and transcriptional regulators interact with mechanical forces in real time to direct vertebrate neural tube formation and neural cell fate specification. We study the dynamics of neural tube formation by applying advanced imaging technologies in transgenic avian models and human stem cell models.

Naomi Wray is the Michael Davys Professor in the Department of Psychiatry, University of Oxford. She holds an appointment at the Institute for Molecular Bioscience (IMB) within the University of Queensland. She joined UQ Queensland Brain Institute in 2011 moving to the IMB in 2015. She was Head of the Centre for Population & Disease Genomics within IMB 2018-2023. Her Oxford appointment started in 2023.

Her research focuses on development and application of quantitative genetics and genomics methodologies across complex diseases, disorders and traits, but particularly psychiatric-related traits.

She is a National Health and Medical Research Council (NHMRC) Leadership Fellow, a Fellow of the Australian Academy of Science and a Fellow of the Australian Academy of Health and Medical Science. In 2020 she was awarded the NHMRC Elizabeth Blackburn Award for Leadership in Basic Science and the 2021 International Society of Psychiatric Genetics Ming Tsuang Lifetime Achievement Award. She is a Clarivate Highly Cited researcher.

She was Director of the Program in Complex Trait Genomics (PCTG) funded as an NHMRC Program Grant 2017-2022. She plays a key role in the International Psychiatric Genomics Consortium and established the sporadic ALS Australia systems genomics consortium (SALSA) funded by the MND Research Australia IceBucket Challenge and FightMND. She is a co-investigator on the Australian Genetics of Depression Study (AGDS) and is currently launching the AGDS-Cello project focussed on establishing a cell line resource from participants with a detailed history of anti-depressant use and response measures. She is part of an NHMRC Synergy (2023-2027) "Rhythms and blues: Personalising care for body clock dysfunction in mood disorders".

She is secretary of the International Society of Psychiatric Genetics, and is on the editorial advisory boards of JAMA Psychiatry, Neuron, Royal Society Open and Research Directions: Depression.

My group studies the role of cadherin cell adhesion molecules in morphogenesis and tumor development. E-cadherin is a key mediator of cell-cell recognition. It participates in tissue patterning and its dysfunction contributes to tumor progression and invasion.

Associate Professor Yap is the group leader for Cadherin cell adhesion molecules, Epithelial morphogenesis & Cell locomotion research at the IMB.

Dr Loic Yengo is a Professor of Statistical Genomics at The University of Queensland (UQ) and Group Leader of the Statistical Genomics Laboratory within UQ's Institute for Molecular Bioscience. He was awarded a prestigious Snow Medical Research Fellowship in 2024 to dramatically advance the use of genomics to prevent chronic disease such as type 2 diabetes, heart disease and Alzheimer's, with a particular focus on increasing participation of people with diverse ancestries. After completing a PhD in applied mathematics and statistics at the University of Lille (France) in 2014, he joined UQ in 2016 for postdoctoral training in Quantitative and Statistical Genetics. Loic started his own lab in 2020 to investigate the causes and consequences of genetic variation within and between human populations. His group develops and applies novel statistical methods to analyse large volumes of genomic data. Loic's research has contributed to improving understanding of the genetic and phenotypic consequences of non-random mating (inbreeding and assortative mating) in human populations and has led to identifying novel genetic variants associated with complex traits and diseases. Loic was named among the top 40 rising stars of research by The Australian newspaper in 2021 and received the UQ Foundation research excellence award the same year. Loic is the 2022 recipient of the Ruth Stephens Gani Medal of the Australian Academy of Science recognizing outstanding contributions to research in human genetics, and was named in Nature Medicine's 2022 Yearbook among 11 early-career researchers "to watch".

In 2024, he was the recipient of the American Society of Human Genetics Early Career Award and a Snow Medical Research Foundation Fellowship to accelerate the deployment of genomic risk prediction in the clinic and improve the benefit of genomic medicine in all populations.